Bronchiectasis Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments
Bronchiectasis Pipeline Analysis report covers 12 drugs currently in different phases of development. Bronchiectasis is a chronic disease characterised by thickening and inflammation of the walls of the bronchi along with the damaged air passages. These damaged air passages allow bacteria and mucus to build up in the lungs leading to frequent infections and blockage of the airways. Symptoms include persistent cough, production of large amounts of sputum and mucus, trapped particles, and pus, shortness of breath and chest pain. Treatment options include medicines (antibiotics, bronchodilators, expectorants, or mucus-thinning), hydration, and chest physical therapy (CPT).
The report provides bronchiectasis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report Aradigm Corporation, Regend Therapeutics Co., Ltd, and Insmed Incorporated among others.
By Molecule Type
By Route of Administration